Global Cancer Biological Therapy Market by Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), Route of Administration (Intramuscular, Intravenous, Subcutaneous), End-Users - Forecast 2024-2030- Product Image

Sale

Global Cancer Biological Therapy Market by Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines), Route of Administration (Intramuscular, Intravenous, Subcutaneous), End-Users - Forecast 2024-2030

Report
186 Pages
March 2024
Region: Global
360iResearch™
ID: 5336922

UP TO €846EUR$875USD£717GBP OFF until Dec 31^st 2024

The Cancer Biological Therapy Market size was estimated at USD 64.95 billion in 2023, USD 72.42 billion in 2024, and is expected to grow at a CAGR of 11.60% to reach USD 140.04 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Biological Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Biological Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biological Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Biogen Inc., bluebird bio, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Cancer Biological Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Cancer Growth Blockers
- Monoclonal Antibodies
- Vaccines
Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
End-Users
- Hospitals
- Specialty Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Cancer Biological Therapy Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Biological Therapy Market?
What are the technology trends and regulatory frameworks in the Cancer Biological Therapy Market?
What is the market share of the leading vendors in the Cancer Biological Therapy Market?
Which modes and strategic moves are suitable for entering the Cancer Biological Therapy Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cancer Biological Therapy Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of cancer with increased healthcare expenditure
5.1.1.2. Increasing awareness regarding benefits of cancer biological therapy
5.1.1.3. Favorable government policies for cancer based therapies
5.1.2. Restraints
5.1.2.1. Capital intensive treatment
5.1.3. Opportunities
5.1.3.1. Ongoing technological advancements in cancer biologics
5.1.3.2. Rising research and development activities for development of efficient cancer biological therapies
5.1.4. Challenges
5.1.4.1. Probable effects of anti-cancer drug therapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Cancer Biological Therapy Market, by Product

6.1. Introduction
6.2. Cancer Growth Blockers
6.3. Monoclonal Antibodies
6.4. Vaccines

7. Cancer Biological Therapy Market, by Route of Administration

7.1. Introduction
7.2. Intramuscular
7.3. Intravenous
7.4. Subcutaneous

8. Cancer Biological Therapy Market, by End-Users

8.1. Introduction
8.2. Hospitals
8.3. Specialty Centers

9. Americas Cancer Biological Therapy Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cancer Biological Therapy Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biological Therapy Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. AbbVie, Inc
13.1.2. Amgen Inc.
13.1.3. Astellas Pharma Inc.
13.1.4. AstraZeneca PLC
13.1.5. Bausch Health Companies Inc.
13.1.6. Bayer AG
13.1.7. Biogen Inc.
13.1.8. bluebird bio, Inc.
13.1.9. Bristol-Myers Squibb Company
13.1.10. Eisai Co., Ltd.
13.1.11. Eli Lilly and Company
13.1.12. F. Hoffmann-La Roche Ltd
13.1.13. Gilead Sciences, Inc.
13.1.14. GlaxoSmithKline PLC
13.1.15. Hikma Pharmaceuticals PLC
13.1.16. Incyte Corp
13.1.17. Johnson & Johnson Services, Inc,
13.1.18. Merck & Co., Inc.
13.1.19. Novartis AG
13.1.20. Otsuka Pharmaceutical Co., Ltd
13.1.21. Pfizer Inc.
13.1.22. Sanofi SA
13.1.23. Spectrum Pharmaceuticals, Inc.
13.1.24. Takeda Pharmaceutical Company Limited
13.1.25. Teva Pharmaceutical Industries Ltd
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
FIGURE 7. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 10. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 14. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 26. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 27. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 29. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 30. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 43. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 46. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 52. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 70. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 81. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 83. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 86. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 87. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 89. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 92. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 93. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 98. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 99. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 107. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 110. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 113. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 125. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 126. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 134. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 143. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 144. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 145. CANCER BIOLOGICAL THERAPY MARKET LICENSE & PRICING

Companies Mentioned

AbbVie, Inc
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bausch Health Companies Inc.
Bayer AG
Biogen Inc.
bluebird bio, Inc.
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Hikma Pharmaceuticals PLC
Incyte Corp
Johnson & Johnson Services, Inc,
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd
Pfizer Inc.
Sanofi SA
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	186
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 72.42 Billion
Forecasted Market Value ( USD ) by 2030	$ 140.04 Billion
Compound Annual Growth Rate	11.6%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,763GBP €3625EUR$3,749USD£3,070GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,500GBP €4593EUR$4,749USD£3,889GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,238GBP €5560EUR$5,749USD£4,708GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£4,975GBP €6527EUR$6,749USD£5,527GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,449GBP €8461EUR$8,749USD£7,165GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Bispecific Antibody Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Indication (Cancer, CNS Conditions), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Global Combination Antibody Therapy Market by Type (Antibody-Drug Conjugates, Bispecific Antibodies, Chemotherapy-Monoclonal Antibodies), Indication (Cancer, HIV), Route of Administration, Distribution Channel, End-Use - Forecast 2024-2030

Cancer Monoclonal Antibodies Global Market Report 2024

Global Bispecific Antibody Therapeutics Contract Manufacturing Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Global Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029